Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07148414 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SPY072 in Rheumatic Disease

Study acronym: SKYWAY-RD
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 64 of 64 sitesv16 Show 1 more changeShow less
    • Site details revised at 64 of 64 sites
  2. Trial sites expanded: 57 → 63 locationsv15
  3. Study sites: 57 to 63v14
  4. Trial sites expanded: 41 → 57 locationsv13
  5. Study sites: 29 to 41 Eligibility criteria shortened, about 20 wordsv12 Show 1 more changeShow less
    • Eligibility criteria shortened, about 20 words

    See this version in full on ClinicalTrials.gov ↗

Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 19 to 29v11
  2. Study sites: 13 to 19v10
  3. Study sites: 11 to 13v9
  4. Study sites: 10 to 11v8
  5. Study sites: 8 to 10v7
  6. Study sites: 7 to 8v6
  7. Study sites: 5 to 7v5
  8. Study sites: 4 to 5 Secondary endpoints: details revised at 1 of 3 entriesv4 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 3 entries
  9. Study sites: 3 to 4v3
  10. Primary completion date: Mar 27, 2028 to Oct 31, 2026 Completion date: Mar 27, 2028 to Mar 31, 2028 · Secondary endpoints: details revised at 1 of 3 entriesv2 Show 2 more changesShow less
    • Completion date: Mar 27, 2028 to Mar 31, 2028
    • Secondary endpoints: details revised at 1 of 3 entries
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
Trial Details
NCT Number NCT07148414
Lead Sponsor Spyre Therapeutics, Inc.
Conditions Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Enrollment 285 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov